Q&A: Etrasimod offers orally delivered therapy option in UC

Etrasimod helped patients with moderate-to-severe ulcerative colitis achieve clinical and endoscopic improvements, according to research published in Gastroenterology.In the study, researchers randomly assigned patients to 12 weeks of therapy with 1 mg or 2 mg once-daily etrasimod (APD334, Arena Pharmaceuticals) or placebo. Patients had a modified Mayo score between 4 and 9, endoscopic subscores of at least 2 and rectal bleeding subscores of at least 1. The primary endpoint was an increase in the mean improvement in Mayo score from baseline to week 12. Secondary endpoints included theRead More

Share on facebook
Share on twitter
Share on linkedin